Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 8,667 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 8,667 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $38.27, for a total value of $331,686.09. Following the completion of the transaction, the director owned 10,500 shares of the company’s stock, valued at approximately $401,835. This represents a 45.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Robert Glassman also recently made the following trade(s):

• On Wednesday, September 9th, Robert Glassman sold 8,000 shares of Pharvaris stock. The stock was sold at an average price of $37.55, for a total transaction of $300,400.00.

Pharvaris Price Performance

Shares of Pharvaris stock opened at $38.00 on Friday. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $43.25. The business has a 50 day moving average price of $35.35 and a 200 day moving average price of $31.69. The company has a market capitalization of $2.49 billion, a P/E ratio of -12.46 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, research analysts expect that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the stock. HSBC raised shares of Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. Wells Fargo & Company raised their price objective on Pharvaris from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. Rosenblatt Securities set a $60.00 price objective on Pharvaris in a research report on Wednesday, September 9th. Oppenheimer reiterated an “outperform” rating and issued a $75.00 target price on shares of Pharvaris in a research note on Tuesday, September 8th. Finally, New Street Research set a $60.00 target price on Pharvaris in a research report on Friday, August 14th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pharvaris presently has an average rating of “Moderate Buy” and an average price target of $59.87.

Hedge Funds Weigh In On Pharvaris

A number of hedge funds have recently made changes to their positions in the stock. venBio Partners LLC purchased a new stake in Pharvaris during the second quarter valued at about $160,569,809. 5AM Venture Management LLC acquired a new stake in Pharvaris during the 2nd quarter worth approximately $27,581,008. BlackRock Inc. purchased a new position in Pharvaris in the second quarter valued at approximately $26,677,000. Elmind Capital LP purchased a new position in Pharvaris in the second quarter valued at approximately $18,180,435. Finally, Seven Fleet Capital Management LP lifted its position in Pharvaris by 144.6% during the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock valued at $26,782,000 after buying an additional 457,804 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.